Investors.invivyd.com

Invivyd Announces Partnership With Population Health Partners to

WEB-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future …

Actived: 1 days ago

URL: https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-partnership-population-health-partners

Invivyd Receives Healthcare Common Procedure Coding System …

WEBProduct-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224) defines reimbursement for product …

Category: Health Go Health

Invivyd Reports Full Year 2023 Financial Results and Recent …

WEBWALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable …

Category: Health Go Health

Invivyd to Pursue Rapid Immunobridging Pathway to Potential …

WEBPathway leverages immunobridging approach via serum virus neutralizing antibody (sVNA) titers enabled by prior successful COVID-19 treatment clinical trial …

Category: Health Go Health

Invivyd Announces Additional Positive Initial Data from Ongoing …

WEBContinued favorable safety and tolerability profile for all dose levels tested Serum samples from all dose levels tested showed robust neutralization activity against …

Category: Health Go Health

Invivyd Announces Positive Initial Data from Ongoing Phase 1 …

WEBVYD222 has been generally well-tolerated at all dose levels, with no serious adverse events reported to date; As predicted by pre-clinical in vitro testing, early serum …

Category: Health Go Health

Invivyd Announces General Alignment with FDA on Pathway to …

WEBUnique, rapid development pathway for monoclonal antibodies (mAbs) using immunobridging via serum neutralizing titers could be enabled by previously generated …

Category: Health Go Health

Invivyd Announces FDA Authorization for Emergency Use of …

WEBOther than systemic infusion-related reactions and hypersensitivity reactions described previously for Cohort A, the most common (≥2%) treatment-emergent adverse …

Category: Health Go Health

Invivyd Announces Partnership With Population Health …

WEBInvivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19 November 17, 2022

Category: Health Go Health

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 …

WEBInitial primary endpoint data anticipated in late 2023 or early Q1 2024 WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: …

Category: Health Go Health

Invivyd Reports Full Year 2022 Financial Results and Business

WEBWALTHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from …

Category: Health Go Health

Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy

WEBWALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from …

Category: Health Go Health

Adagio Therapeutics Partners with Biocon Biologics to Bring …

WEBWaltham, MA – July 26, 2021 – Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and …

Category: Health Go Health

Invivyd Elects Two New Independent Members to its Board of …

WEBWALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious …

Category: Health Go Health

INVIVYD Q3 2023 FINANCIAL RESULTS & BUSINESS …

WEBEnrollment completed in CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the prevention of symptomatic COVID-19. Company expects to have initial CANOPY …

Category: Health Go Health

Adagio Therapeutics Announces ADG20 Phase 1 Data and …

WEBPreliminary Data from Ongoing Phase 1 Trial in Healthy Volunteers Support ADG20 Safety and Pharmacokinetic Profile and SARS-CoV-2 Neutralizing Activity …

Category: Health Go Health

Clive Meanwell, M.D.

WEBDr. Meanwell was a founder of The Medicines Company and was a director of The Medicines Company from 1996 until The Medicines Company was acquired by Novartis …

Category: Medicine Go Health

Adagio Therapeutics Appoints Leading Pharmaceutical and …

WEBWaltham, MA – July 29, 2021 – Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and …

Category: Health Go Health

Adagio Therapeutics to Participate in Cowen 41st Annual Health …

WEBWaltham, MA – February 22, 2021--- Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today …

Category: Coronavirus Go Health

Adagio Therapeutics Raises $80M Series B Round to Further …

WEB-Lead antibody - ADG20 - expected to advance to clinical studies in early 2021, offers potential best-inclass treatment and durable protection against SARS-CoV …

Category: Health Go Health

Evercore ISI 6th Annual HealthCONx Conference

WEBThe Investor Relations website contains information about Invivyd's business for stockholders, potential investors, and financial analysts.

Category: Health Go Health

Adagio Therapeutics to Present at the 40th Annual J.P. Morgan

WEBWALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, …

Category: Health Go Health